argenxARGX
ARGX
About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Employees: 1,639
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
129% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 34
107% more call options, than puts
Call options by funds: $375M | Put options by funds: $181M
24% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 117
11% more funds holding
Funds holding: 352 [Q3] → 390 (+38) [Q4]
11% more capital invested
Capital invested by funds: $19B [Q3] → $21B (+$2.01B) [Q4]
2.07% less ownership
Funds ownership: 58.59% [Q3] → 56.52% (-2.07%) [Q4]
10% less funds holding in top 10
Funds holding in top 10: 20 [Q3] → 18 (-2) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$680
5%
upside
Avg. target
$770
19%
upside
High target
$1,100
71%
upside
8 analyst ratings
7 positive
88%
1 neutral
13%
0 negative
0%
Citigroup Samantha Semenkow 27% 1-year accuracy 3 / 11 met price target | 23%upside $796 | Buy Maintained | 17 Apr 2025 |
Wedbush David Nierengarten 40% 1-year accuracy 46 / 114 met price target | 11%upside $715 | Outperform Reiterated | 16 Apr 2025 |
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target | 12%upside $720 | Buy Reiterated | 11 Apr 2025 |
Guggenheim Yatin Suneja 24% 1-year accuracy 8 / 33 met price target | 71%upside $1,100 | Buy Maintained | 10 Mar 2025 |
Baird Joel Beatty 32% 1-year accuracy 12 / 38 met price target | 5%upside $680 | Neutral Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 12 articles about ARGX published over the past 30 days
Negative
Investors Business Daily
8 hours ago
Argenx Stock Extends Rally In A Base As Earnings Loom
Argenx stock is rising Wednesday as the major indexes sell off. The autoimmune disease treatment stock is climbing in an early-stage base.
Neutral
GlobeNewsWire
2 days ago
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. “Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs.
Positive
Zacks Investment Research
6 days ago
Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Argenx (ARGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 week ago
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
Positive
Zacks Investment Research
2 weeks ago
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Benzinga
2 weeks ago
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Neutral
GlobeNewsWire
2 weeks ago
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
Positive
Investors Business Daily
2 weeks ago
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment. The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.
Positive
Reuters
2 weeks ago
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday.
Neutral
GlobeNewsWire
2 weeks ago
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go' or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025, 11:45 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART® Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). “Today's FDA approval provides a new self-injection option across both approved indications in the U.S. that is designed for patients who seek more independence with their treatment,” said Luc Truyen M.D.
Charts implemented using Lightweight Charts™